About This Treatment

Myeloma Clinical Trials

Recently Updated

Phase 1/2 Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation (ASCT) for Treatment in Relapsed / Refractory Multiple Myeloma (Titanium 1)

This study is a phase 1/2 trial of Tinostamustine conditioning and autologous stem cell transplantation for treatment in relapsed / refractory multiple myeloma. The main purpose of this study is to assess the safety and tolerability of Tinostamustine as conditioning in the phase 1 part of the study and the safety, tolerability and efficacy of Tinostamustine in phase 2.

Learn more about this trial

Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of EDO-S101 in patients with relapsed/refractory hematologic malignancies. All patients will receive EDO-S101.

Learn more about this trial

Treatment Information
Developed By

Mundipharma EDO GmbH

Treatment Classifications
Additional Names
  • EDO-S101

Create Your Account

Create your account today and get matched to myeloma treatments and trials around the US.

  • Find treatments with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new treatments become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST